Mechanism of the condensation reactions of methylglyoxal, phenylglyoxal and benzoylacetaldehyde with phenolic compounds have been discussed. It was observed that the reaction mechanisms changed depending on the type of the phenolic and also dicarbonyl compounds. While, methylglyoxal gave the angular methyl derivative of naphthofuraranonaphthofuran with 2‐naphthol, phenylglyoxal and its p‐chloro and p‐methoxy derivatives formed benzo[b]naphtho[2,1‐f]oxepine‐13‐ones. However, resorcinol behaved different and gave 2‐phenyl‐3‐(2,4‐dihydroxy)‐6‐hydroxy‐benzo[b]furans with phenylglyoxal derivatives. 2‐Phenyl‐4‐(2‐hydroxynaphmyl)‐4H‐naphtho[b]pyran was produced from the reaction of benzoylacetaldehyde and 2‐naphthol, but the reaction product was 3,9‐dihydroxy‐6‐phenyl‐6,12‐methano‐12H‐dibenzo[1,3]dioxocin when the same carbonyl compound reacted with resorcinol.
Eukaryotic elongation factor 2 kinase (eEF-2K) is an unusual alpha kinase involved in protein synthesis through phosphorylation of elongation factor 2 (EF2). eEF-2K is highly overexpressed in breast cancer, and its activity is associated with significantly shortened patient survival and proven to be a potential molecular target in breast cancer. The crystal structure of eEF-2K remains unknown, and there is no potent, safe, and effective inhibitor available for clinical applications. We designed and synthesized several generations of potential inhibitors. The effect of the inhibitors at the binding pocket of eEF-2K was analyzed after developing a 3D target model by using a domain of another α-kinase called myosin heavy-chain kinase A (MHCKA) that closely resembles eEF-2K. In silico studies showed that compounds with a coumarin−chalcone core have high predicted binding affinities for eEF-2K. Using in vitro studies in highly aggressive and invasive (MDA-MB-436, MDA-MB-231, and BT20) and noninvazive (MCF-7) breast cancer cells, we identified a lead compound that was highly effective in inhibiting eEF-2K activity at submicromolar concentrations and at inhibiting cell proliferation by induction of apoptosis with no toxicity in normal breast epithelial cells. In vivo systemic administration of the lead compound encapsulated in single lipid-based liposomal nanoparticles twice a week significantly suppressed growth of MDA-MB-231 tumors in orthotopic breast cancer models in nude mice with no observed toxicity. In conclusion, our study provides a highly potent and in vivo effective novel small-molecule eEF-2K inhibitor that may be used as a molecularly targeted therapy breast cancer or other eEF-2K-dependent tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.